, Tracking Stock Market Picks
Enter Symbol:
Cv Therapeutics, Inc. (CVTX) [hlAlert]

up 27.53 %

Cv Therapeutics, Inc. (CVTX) rated Buy with price target $18 by Benchmark

Posted on: Monday,  Feb 23, 2009  8:25 AM ET by Benchmark

Benchmark rated Buy Cv Therapeutics, Inc. (NASDAQ: CVTX) on 02/23/2009, when the stock price was $15.69. Since
then, Cv Therapeutics, Inc. has gained 27.53% as of 04/17/2009's recent price of $20.01.
If you would have followed this Benchmark's recommendation on CVTX, you would have gained 27.53% of your investment in 53 days.

CV Therapeutics is a biopharmaceutical company engaged in the discoveryand development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. The company has several research and preclinical development programs designed to bring additional drug candidates into human clinical testing. The company is conducting clinical trials for two of our drug candidates, including ranolazine, which is in its second Phase III trial.

The Benchmark Company, LLC is a full-service Broker Dealer dedicated to meeting the needs of institutional and private clients. Operating from offices in New York, Boston, San Francisco, Philadelphia, Los Angeles and San Diego, Benchmark is committed to the highest standards of performance and service. This is a clear message to our clients that the company will continue to distinguish itself through outstanding service into the future.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/23/2009 8:25 AM Buy
15.69 18.00
as of 7/16/2009
1 Week   
1 Month   
3 Months up  28.35 %
1 YTD up  27.53 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy